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Rapid up-regulation of mdrl expression by anthracyclines in a classical
multidrug-resistant cell line
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S_ummary Studies were carried out in a variant human multidrug-resistant (MDR) cell line CEM/A7R, which
expresses very low levels of mdrl mRNA and P-glycoprotein (P-gp). The induction of mdrl RNA expression
by three anthracycines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine,
vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative
level of mdrl expression was expressed as ratio of mdrl to the internal RNA (actin). A significant increase
(P<0.02) in expression of mdrl was noted within 4 hrs of exposure to 1.5 ig ml-' daunorubicin or epirubicin.
Neither vinblastine nor vincristine had any effect on mdrl levels after an 8 h exposure. With increasing
concentrations of daunorubicin or epirubicin in a fixed 24 h time period, mdrl expression increased, although
a biphasic response was seen. Based on MRK 16 binding, an increase in P-gp levels was seen in the CEM/A7R
line after a 24 h exposure to 1 Zig ml1 l daunorubicin or epirubicin. The rapid increase in mdurl expression after
a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdrl
expression may have an important role in the development of drug-resistant tumours.
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Multidrug resistance (MDR) is a common problem in acute
leukaemia. Patients often relapse with unresponsive disease
following an initial response to treatment with cytotoxic
drugs. One form of drug resistance commonly seen in
relapsed acute leukaemia is related to the overexpression of
P-glycoprotein (P-gp), a marker of the classical MDR
phenotype (Deuchars and Ling, 1989). P-gp, encoded by the
mdrl gene (Goldstein et al., 1992), is believed to function as
an energy-dependent, efflux pump resulting in the decreased
accumulation of several structurally unrelated drugs includ-
ing anthracyclines, vinca alkaloids and epipodophyllotoxins
(Hayes and Wolf, 1990). The classical MDR phenotype can
be partially reversed by a wide range of structurally diverse
compounds such as verapamil (Tsuruo et al., 1981; Ford and
Hait, 1990) and cyclosporin A (Slater et al., 1986).
A number of studies in human acute leukaemia have dem-
onstrated that expression of the mdrl gene is usually low or
undetectable before treatment but increased after
chemotherapy. In addition, there appears to be a direct
correlation between expression of the mdrl gene and the
outcome of chemotherapeutic treatment (Chan et al., 1990;
Goasguen et al., 1993).
The acquisition of drug resistance during chemotherapy is
usually thought to be due to the selection of drug-resistant
cells. In human cells, rapid up-regulation of ,ndrl expression
by cytotoxic drugs has not been demonstrated by conven-
tional hybridisation techniques. Immunocytochemical stain-
ing with the monoclonal antibody (MAb) MRK16 in a
human pleural mesothelioma line (Licht et al., 1991) or MAb
C219 in a human lung adenocarcinoma line (Chevilard et al.,
1992) has only shown an increase in the number of P-gp-
positive cells after several weeks of treatment with anti-
cancer drugs. However, overexpression of mdrl in rodent but
not human cells (Chin et al., 1990a) was seen 8 h following
treatment with cytotoxic drugs, suggesting an important but
unexplained difference in the regulation of mdrl expression
between human and rodent tissues. More recently, using the
highly sensitive polymerase chain reaction (PCR) assay, in-
creased expression of human mdrl was observed 3-5 days
following cytotoxic drug treatment, a period defined by mic-
roscopically visible cell damage (Chaudhary and Roninson,
1993).
In contrast, mdrl expression has been shown to be rapidly
inducible in human cell lines in response to heat shock,
arsenite (Chin et al., 1990b; Kioka et al., 1992a) or
differentiating agents (Bates et al., 1989; Mickley et al.,
1989). Using a CAT (chloramphenicol acetyltransferase)
assay, the proximal promoter of the mdrl gene may be
directly activated by some cytotoxic drugs (Kohno et al.,
1989), as well as heat shock (Kioka et al., 1992b; Miyzaki et
al., 1992), serum deprivation and differentiating agents
(Tanimura et al., 1992; Ferrandis and Benard, 1993). How-
ever, the relevance of this change in the function of an
exogenous promoter linked to a reporter gene is uncertain in
view of the difficulties in detecting up-regulation of the
endogenous mdrl gene following the administration of
cytotoxic drugs (Tanimura et al., 1992; Ferrandis and
Benard, 1993).
The apparent species differences in the response of the
mdrl gene to exposure to anthracyclines led us to examine
this issue more carefully in a variant MDR cell line in order
to determine whether human mdrl gene expression was
inducible. Using Northern blotting, the induction of mdrl by
three anthracyclines, doxorubicin (DOX), daunorubicin
(DAU) and epirubicin (EPI), and two vinca alkaloids (vin-
cristine and vinblastine) was investigated in a cloned, variant
cell line CEM/A7R known to express low levels of P-gp. A
rapid induction of mdrl was observed, suggesting that in this
model P-gp expression was inducible and, thus, by inference,
that the development of clinical drug resistance may involve
both the induction and selection of drug-resistant cell
populations.
Materials and methods
Materials
DOX, DAU, vinblastine (VLB), vincristine (VIN) and
etoposide (VP-16) were commercially obtained from David
Bull Laboratories (Melbourne, Australia), EPI was pur-
chased from Farmitalia (Melbourne, Australia). RPMI-1640
was purchased as a powder (Gibco Labs) and supplemented
with 10% fetal calf serum (Flow Labs, Australia) gentamicin
(80jgml-'), minocycine (I igml-'), Hepes (20mM),
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sodium bicarbonate (0.21%) and glutamine (0.8 mm).
Monoclonal antibodies to P-gp were generously provided by
Dr Takashi Tsuruo (Division of Experimental Chemo-
therapy, Japanese Foundation for Cancer Research).
Fluorescein-labelled goat anti-mouse immunoglobulin was
purchased from Becton Dickinson (Sydney, Australia). The
cDNA probe pHDR5A was a gift from Dr M Gottesman
and Dr Ira Pastan (Laboratory of Molecular Biology,
National Institutes of Health, Bethesda, MD, USA). The
cDNA human 7-actin plasmid was a gift from Dr Joe
Trapani (Austin Research Institute, Melbourne, Australia).
Dimethyl sulphoxide and propidium iodide were obtained
from Sigma (St Louis, MO, USA) and fluo-3 from Molecular
Probes (Eugene, OR, USA).
Cell lines and culture conditions
The low-level DOX-resistant CEM/A7 cell line (Zalcberg et
al., 1994) was obtained by stepwise selection in increasing
concentrations of DOX of the drug-sensitive, CCRF-CEM
parental cell line, originally derived from a patient with a
T-cell lymphoblastic leukaemia (Foley et al., 1965). The
CEM/A7 line has been characterised as a classical MDR line
with overexpression of P-gp and cross-resistance to a number
of structurally unrelated cytotoxics including anthracyclines,
vinca alkaloids and VP-16 (Zalcberg et al., 1994). The CEM/
A7 line was maintained in RPMI-1640 supplemented with
10% fetal calf serum (FCS) and 0.07Lgml-' of DOX and
cultured at 37C in a humidified chamber containing 5%
carbon dioxide in air.
A vanrant of the CEM/A7 line was developed by growing
this cell line in the absence of DOX for more than 2 years.
The expression of P-gp in the variant line was decreased to
less than one-quarter of that in the CEM/A7 line. The
variant line was subcloned in 96-well plates by a limited
dilution technique. A single clone was identified 2 weeks
later, transferred to 24-well plates and subsequently
expanded. The cloned variant line, referred to as CEM/A7R,
was used throughout this study. This line was not exposed to
DOX or other P-gp substrates except in the specific
experiments detailed below. All lines were mycoplasma free
according to the Mycoplasma T C Rapid Kit (Gen-Probe,
San Diego, CA, USA) at the time of these experiments.
Drug treatment andsample collection
CEM/A7R cells in exponential growth phase were collected 2
days after subculture. The cells were washed, counted and
resuspended at a total cell number of 5 x 106 to 1 x 107 in
20 ml of fresh medium. The cells were treated with either
DOX, EPI, DAU VP-16, VIN or VLB and harvested at
designed time points. Cell viability was determined (after
staining by trypan blue) using phase-contrast microscopy to
detect cells of abnormal size or granularity. Non-viable cells
were excluded from flow cytometric analysis by propidium
iodide (Sigma) staining.
Growth assays
The sensitivity of each of the cell lines to a variety of
chemotherapeutic drugs was determined by a standard
growth inhibition assay (Tsuruo et al., 1981). Briefly, after
determining cell viability and adjusting the final concentra-
tion of cells in flat-bottomed 12-well plates to 2 x 10 ml-',
varying concentrations of DOX, DAU or EPI were added to
each well. The cells were incubated in humidified chambers at
37C for 3 days and counted using an automated Coulter
counter (Hu et al., 1990). Results are expressed as the in-
crease in cell numbers in drug-exposed cells as a percentage
of the increase in control cells (Tsuruo et al., 1981). All
assays were carried out in triplicate under sterile conditions.
The IC50 for each drug was determined by alculating the
drug concentration required to inhibit cell growth by 50%.
P-gp expression
Flow cytometry was used to measure P-gp expression.
Exponentially growing cells were collected and washed three
times in medium containing 10% FCS. MRK16, a MAb to
an external epitope of P-gp (final concentration 5ggml-'),
was added to cells at room temperature for 20 min. A non-
specific murine monoclonal antibody (IgG2., Becton Dickin-
son) was used as the control. After a further three washes,
cell pellets were resuspended in the same volume of
phosphate-buffered saline (PBS) containing a 1:10 dilution of
a fluorescein-conjugated goat anti-mouse antibody (Becton
Dickinson) for 20 min at room temperature in the dark. Cells
were washed again (x 3) and then analysed in a FACScan
flow cytometer (Becton Dickinson, Sydney, Australia). Mean
fluorescence intensity was recorded for each tested popula-
tion (after correcting for non-specific binding) to provide an
estimate of relative MRK-16 binding.
RNA extraction and Northern blot analvsis
RNA was isolated by the guanidinium
thiocyanate-phenol-chloroform extraction method des-
cribed by Chomczynski and Sacchi (1987). Cells grown under
different conditions were collected and washed three times
with cold sterilised PBS (0.1% diethylene pyrocarbonate) by
centrifuging at 500 g for 5 mins at 4'C. Samples not subjected
to immediate RNA extraction were stored at -70'C. For
RNA extraction, a denaturing solution containing 4 M
guanidinium thiocyanate, 25 mM sodium citrate pH 7, 0.5%
sarcosyl and 0.1 M 2-mercaptoethanol was added to the cell
pellets. Genomic DNA was sheared by passage through a 21
G needle. Sequentially 2M sodium acetate pH 4.0, phenol
(water saturated) and a chloroform-isoamylalcohol mixture
(49:1) were added before cooling the mixture on ice for
15 min. The suspension was centrifuged at 10 000 g for
20 mins at 4C and RNA in the aqueous phase was
precipitated by the addition of one volume ofisopropanol at
-20OC for 1 h. Sedimentation at I0000g for 20min at 4C
was again performed. The resulting RNA pellets were trans-
ferred to microtubes, dissolved in 0.3 ml of the denaturing
solution, precipitated with two volumes of isopropanol at
-20-C for 1 h, centrifuged for IOmin at 4-C and washed
with 75% ethanol before being vacuum dried and dissolved
in TE buffer pH 8.0 (10mM Tris pH 7.4, 0.1 mM EDTA
pH 8.0) at 2jigld1'.
Northern blot analysis
Twenty micrograms of total cellular RNA was size frac-
tionated on a 1.5% agarose gel containing 2.2 M for-
maldehyde and transferred onto nylon filters (Hybond-N,
Amersham UK) for mdrl hybridisation. The filters were
probed with the plasmid pHDR5A containing a 1.4 kb
cDNA for mdrl (Ueda et al., 1987) and then reprobed with a
32P-labeled human E-actin cDNA for normalisation. The
pHDR5A probe predominantly recognises the mdrl gene
under the high-stringency conditions used in this study. The
filters were prehybridised overnight at 42 C in hybridisation
buffer containing 50% formamide, 5 x SSPE (1 x SSPE con-
taining 0.15 M sodium chlonrde, 0.001 M sodium dihydrogen
phosphate and 0.001 M EDTA), 5 x Denhardt's solution,
0.5% sodium dodecyl sulphate (SDS) and 1% skimmed milk
powder. Hybridisation was carried out in hybridisation
buffer. The pHDR5A and y-actin cDNAs were randomly
pimed with [nPJi4dCTP (3000 Ci mmoli') and pHDR5A, or
y-actin cDNA emitting 106 c.p.m. were added to each milli-
litre of hybridisation buffer. The filters were washed sequen-
tially in 2 x SSPE with 0.1% SDS at 42'C for 15m,
1 x SSPE with 0.1% SDS at 65'C for 30min and finally
0.1 x SSPE with 0.1% SDS at room temperature for 15 min.
The filters were then exposed to X-ray film at - 70'C using
intensifying screens and the radioactive signals quantitated by
scanning on a phosphoimager using Image Quant software
(Moleular Dynamics, Melbourne, Australia). This has theadvantage of being quantitatively accurate over five orders of
magnitude and overcomes the problem of signal saturation
inherent in autoradiography.
Reslts
The studies described in this report were carried out in a
variant human leukaemia MDR cell line, CEM/A7R. This
line was derived from a classical MDR cell line CEM/A7,
selected for low-level DOX resistance by stepwise selection of
the parental line CCRF-CEM cultured in increasing concent-
rations of DOX (Zalcberg et al., 1994). The resistant line
CEM/A7 was maintained in conditioned medium containing
0.07pgmP-' of DOX. The variant line (now stable for over
12 months) was established by culturing the CEM/A7 cells in
the absence of DOX before being subcloned and designated
the CEM/A7R line. Flow cytometric analysis of these lines
using the MAb MRK16 demonstrated that, in the CEM/
A7R line, P-gp expression was approximately 10% of that in
the CEM/A7 line (see below). The decreased expression of
P-gp was accompanied by an increase in drug accumulation
(data not shown) and a decrease in drug resistance (Table I).
Compared with the parental, sensitive cell line CCRF-CEM,
the variant CEM/A7R line was 4- to 5-fold more resistant to
DOX or EPI and as sensitive to DAU. In contrast, the
CEM/A7 line was 20-fold more resistant to DOX and EPI
and 4-fold more resistant to DAU than the sensitive line
(Table I).
The induction of the mdrl gene by DOX, DAU or EPI
was analysed by Norther blotting. The comparison of mdrl
expression in the three cell lines was quantitated by scanining
Northern blots on a phosphorimager as described previously.
No signal was seen in Northern analysis of the sensitive line
with progressively stronger signals seen in the CEM/A7R and
CEM/A7R and CEM/A7 lines (Figure la). After the data
had been normalised with respect to the CCRF-CEM signal,
the baseline ratios of mdrl to the internal RNA control,
E-actin, were 0.% and 0.20 for the CEM/A7 and CEM/A7R
lnes respectively (Figure lb).
Equal concentrations of all drugs were used for the pur-
pose of comparison. The concentrations used were generally
greater than the IC50 ofeach ofthese agents when tested in a
standard 3 day growth assay (see Table I). Following an 8 h
exposure to 1.5 pg ml-' DOX, DAU, EPI, or VP16, the ratio
of mdrl/actin expression in the CEM/A7R cells (compared
with the untreated control) increased 2- to 4-fold (Figure la
and b). However, after a similar time period, neither VLB
nor VIN had any effect on mdrl expression.
Experiments over a shorter time using fixed drug concent-
rations of 1.5lzgml-' were then conducted. Results were
quantitated as described above and the data expressed as the
ratio of mdrl expression to the internal RNA (actin) control
(Table IL). A significant 3-fold incrase in mdrl expression
was noted within 4 h ofexposure to DAU or EPI and within
6 h of exposure of cells to DOX (P<0.02).
The effect of anthracyclines on up-regulation of mdrl
appeared to be dose related. The concentrations of EPI and
DAU used in the following experiments ranged from 0.1 to
3pgml-' concentrations which inhibited 30-90% of cell
growth in a 3 day cell growth assay. In these experiments, the
time period was fixed at 24 h. With increasing concentrations
ofDOX, mdrl expression relative to the RNA control (actin)
steadily increased (data not shown), whereas a biphasic res-
Table I Resistance of the three cell lines to anthracyclnes
Drug CCRF-CEM CEM/A7R CEM/A7
Doxorubicin 0.03 ± 0.03a 0.14 ± 0.02 0.58 ± 0.13
Epirubicin 0.04 ± 0.02 0.22 ± 0.02 0.72 ± 0.06
Daunomycin 0.04 ± 0.03 0.06 ± 0.03 0.17 ± 0.01
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ponse was seen for EPI (Figures 2 and 3) and DAU (Figure
3).
Drug-treated cells were carefully examined microscopically
(after staining with trypan blue) for visible cell damage as
evidenced by changed cell shape and/or increased granularity.
In the MRK16 binding experiments, cell viability was
estimated simultaneously by using propidium iodide staining.
No evidence ofcell damage or alterations in cell viability was
observed (data not shown).
TIhe effect of the increase in mdrl mRNA levels on the
expression of P-gp was examined using flow cytometry.
CEM/A7R cells expressed significantly less P-gp than the
28S
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Figwe 1 (a) Up-regulation ofndrl gene expression in the CEM/
A7R ceils. CEM/A7R cells in exponential growth phase were
treated with and without 1.5pgml-I of each drug for 8 h. RNA
was then extracted and subjected to Northern blot analysis. The
RNA was hybridised to a [IPJcDNA probe (pHDR5A) specific
for the human mdrl gene under high-stringency conditions. The
same filter was reprobed with }P-labeled human e-actin cDNA
as an internal control to quantify RNA loding in each lane as
described in Materials and methods. The migration of 28S and
18S ribosomal RNA is indicated. The mdil expression of the
parental, sensitive CCRF-CEM and resistant CEM/A7 cells was
also assessed in this experiment. (b) The 32P-labeled mtfl and
-actin bands shown in a were scannel on a phosphorimager
sing Imag Quant Software (Molecular Dynamics) and the
results were expressed as the ratio of mdrl to 7-actin mRNA. A
2- 4-fold increase in ndl expression was seen within 8h of
treatment with the anthracycines and VP16. Tbese expermients
ere on three separate occasions with similar findings.
The data presented are representatiVe of one such experimet.
'IC5,D levels are expressed in ggml-' as the mean ± s.d. determined
from three separate experiments. Each experiment was performed in
tripLicate as described in Materials and methods.UpreIgddon 1 ex fv XF Hu etat
Table H mdrl expression in the CEM/A7R cell line after short time
exposures to three anthracychnes
Tine (hours) DOX DAU EPI
0 0.24 0.04a -
2 0.27 ± 0.11 0.32 ± 0.07 0.26 ± 0.07
4 0.35±0.13 0.58±0.09* 0.74+0.16*
6 0.72 0.14* 0.75 0.17* 0.71 +0.06*
"mrl and e-actin RNA levels in the CEM/A7R cells exposed to
1.5 zgml-' DOX, DAU and EPI for 2, 4 or 6h were quantfied
using a Molcular Dynamics phosphorimager. The ratio of mdrl to
y-actin is given as the mean ± s.d. (calculated from three Northern
blotting analyses of the one experiment). These results were
compared with the ratio of mdl to E-actin in the untreated
CEM/A7R cells (0.24 ± 0.04) and analysed using the Wilcoxon
rank-sum test. *P<0.02 for marked samples. Similar results were
obtained in three identical expenrments.
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Figwe 2 Effects of increasing doses of EPI on up-regulation of
mdrl gene expression in the CEM/A7R line. Cells in exponential
growth phase were treated with (or without) EPI at doses ranging
from 0.1 to 3.0 Igml- for 24h. RNA was extracted and hy-
bridised with 32P-labelled mdrl and t-actin as described
previously.
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CEM/A7 cells (Figure 4). Exposed to 1 jig ml-' EPI or
DAU, CEM/A7R cells showed a 3- to 4-fold increase in P-gp
expression (mean channel fluorescence 177 and 144 respec-
tively) compared with untreated CEM/A7R cells (mean chan-
nel fluorescence 45).
The stability of the increased levels of mdrl and P-gp
expression in response to DOX was tested 3 weeks after the
CEM/A7R cells had been exposed to 1 ,Lgrl' DOX for
24 h. The treated cells were cultured in drug-free medium for
3 weeks before being subjected to a further analysis of mdrl
CEM/A7
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Figie 3 Effect of increasing doses of DAU or EPI on up-
regulation of mdrl in the CEM/A7 line. Cells in exponential
growth phase were treated with (or without) 0.1 -3.0 Lg ml - I EPI
(0-0) and DAU (A-A) for 24h. RNA was extracted and
analysed by Northern blotting as described in Materials and
methods. The comparison of mdrl expression was quantitated by
scanning Northern blots on a phosphorimager as described
previously. Each point represents the mean of triplicate slot blot
analysis; bars give the standard deviation. Similar dose-response
patterns were seen in a repeat experiment.
CCRF-CEM
10° 1ol 102 103 10
FITC fluorescence
Fugwe 4 Flow cytometric analysis of P-gp expression using
MRK-16 binding (filled histogram) compared with an IgG2, con-
trol (unfilled histogram) in the CCRF-CEM, CEM/A7 and the
CEM/A7R lines before and after exposure to EPI or DAU. P-gp
expression was not seen in the CCRF-CEM parental cell line.
CEM/A7R expressed much less P-gp (10-fold) than the CEM/A7
line. CEM/A7R cells were treated with (or without) 1.5ILgml-'
of EPI and DAU for 24 h before measurement of P-gp levels as
described in Materials and methods. P-gp expression was in-
creased more than 3-fold in the treated CEM/A7R cells com-
pared with untreated controls.
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developed Dy contunuous culture ot tne CLM/Al hne m me
absence of DOX. The subcloned variant cell line labelled
CEM/A7R was stable in drug-free medium for over 12
months before conducting the experiments reported in this
study. The CEM/A7R line expressed P-gp to a significantly
lesser extent than the classical MDR line from which it was
derived (Figures 1 and 4). This line appears to be a useful
model for studying clinical drug resistance in so far as it does
not have detectable amplification of the mdrl gene and ex-
presses very low levels ofP-gp in the absence of a continuous
selective pressure.
In order to assess the effects of cytotoxic drugs on mdrl
expression, the ratio of mdrl RNA to an internal RNA
(actin) control was quantitatively analysed following the
exposure ofcells to various drugs by scanning Northern blots
on a phosphorimager. A significant increase (2-fold) in mdrl
expression was observed within 4h of exposure of CEM/
A7R cells to 1.5 1Lg ml-' DAU or EPI and 6h to 1.5Lrg ml-'
DOX (Table II). A 3- to 4-fold increase in mdrl expression
_w_Il rk_ o 0 ___ __ - r -1- I
0.00 0.20 0.40 0.60 0.80 1.oo 1.20 was observed after an 8 h exposure to 1.5 )gml-' DOX,
nconcentration (gg mr1) DAU or EPI (Figure la and b). Increases in mdrl levels also
resulted in an increase in P-gp expression (Figure 4). Neither
5 The stability of te increase .m l a VLB nor VIN had any effect on mdl expression after
sly described was estimated by comparing the resistance exposure to these drugs for 8 h (Figure la and b). In view of
of treated and untreated cells 3 weeks after a 24h the cell doubling time of 24 h for the CEM/A7R line, these
re to 1.5Mgml1' DOX In the intervening 3 weeks both changes in mdr expression are occurring too quickly to be
es were maintained in drug-free medium. The percentage explained by cell selection, suggesting that the induction of
in cell number ofuntreated(-0) or treatedcells(-0) drug resistance may be a first step in the development of
I to increasng concentratons of EPI 3 weeks after a 24 h clinical resistance, with selection occurring as a secondary
re to DOX relative to untreated controls is plotted. Points event nit the means of triplicate determinations aad baevent.
nd deviation. Recently, Chin et al. (1990a) reported the induction of mdrl expression in a rodent cell line as early as 2h after
exposure to anthracyclines. They observed levels as high as
30- to 100-fold greater than in untreated controls, although
no detectable increase in mdrl expression was seen in human
on and measurement of P-gp levels. The mdrl tumour cells. They concluded that species differences in the
and P-gp levels in the DOX-treated CEM/A7R cells promoter sequence and/or consensus binding sites (Ueda et
d 2- to 3-fold higher than the untreated CEM/A7R al., 1987; Hsu et al., 1989; Cornwell, 1990; Ikeguchi et al.,
Lta not shown), corresponding to the 3-fold increase 1991) may account for the induction of nudrl expression in
resistance demonstrated in a growth assay (Figure rodent but not human cell lines. Alternatively, induction may
have been demonstrable in our model because ofthe inherent
capacity of T cells to alter gene expression in response to
environmental stimuli.
om In the study reported by Chin et al. (1990a), no change in
expression of the mdfrl gene was seen following exposure of
man mdrl gene can be induced by environmental rodent cells to vinca alkaloids or epipodophyllotoxins (Chin
such as heat shock or arsenite (Chin et al., 1990b; etal., 1990a). Wealso failed to observe any increaseinmdrl
et al., 1992a) and agents which affect cellular expression in response to VIN or VLB after an 8 h exposure,
tiation (Bates et al., 1989; Mickley et al., 1989). How- although VP16 was associated with an increase in mdrl
e effect of cytotoxic drugs on gene expression and in expression in our system. It is possible that these findings
E MDR phenotype remain poorly understood. Two relate to the sensitivity of the assay system used and hence
hypotheses are equally plausible: selection of pre- further clarification of this phenomenon will depend on more
MDR cells owing to the preferential growth advan- detailed dose and time course experiments now under way in
low numbers of these cells in the presence of our laboratory.
icdrugs or the induction of mdrl expression in cells The precise mechanism underlying up-regulation of the
w P-gp levels. While these two concepts are not mdrl gene by anti-cancer drugs in these human cells is un-
y exclusive, the effect of cytotoxic drugs on the clear but may operate at either the transcriptional or post-
Dn of mdrl gene is likely to be of critical importance transcriptional level. The increse in mdrl levels after the
rstanding how cytotoxic drugs should be used in this exposure of CEM/A7R cells to EPI for 4 h suggests that
changes in the rate of transcription may be important in this
;tudies reported herein were camed out in a variant model. The possible mechanisms responsible for the rapid
ell line (CEM/A7R) with very low levels of mdrl gene induction of mdrl expression are currently under investiga-
on and drug resistance (Table I, Figures 1 and 4). tion in our laboratory. In addition, as variable responses to
was originally derived from a classical MDR human anthracycline analogues, all of which represent substrates for
ia cell line (CEM/A7) initially selected for resistance P-gp, have not previously been identified, studies to clarify
;by a stepwise selection procedure. The CEM/A7 line the interaction between these analogues and the mdrl pro-
laintained in conditioned medium containing moter are also under way.
0.07lrg ml ' DOX (Zalcberg et al., 1994). Induction of mdrl
mRNA could not be demonstrated in this cell line,
presumably because of the continuous selection pressure. In
addition, induction was not seen in the sensitive CCRF-CEM
line (data not shown). A variant MDR cell line was
Aek
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